卵巢上皮癌中MDR1与CA125表达预测化疗效果的价值

Predictive value of MDR1 and CA125 expression in ovarian cancer patients under chemotherapy

目的研究MDR1在卵巢上皮癌中的表达及其在卵巢上皮癌诊疗方面的价值。方法采用荧光定量RT-PCR技术检测卵巢组织中MDR1基因的mRNA含量,化学发光法检测术前及术后每次化疗前血清CA125水平,分析MDR1与CA125及其半衰期的相关性。结果MDR1基因在卵巢上皮癌、良性肿瘤、正常卵巢组织中的表达差异有统计学意义(P<0.01)。34例卵巢上皮癌中,24例CA125升高。MDR1表达与CA125相关关系较弱。在34例卵巢上皮癌患者中,CA125半衰期长的MDRI的表达高于CA125半衰期短者(>25dvs.<16d)(P<0.05)。结论检测MDR1表达可用以预测卵巢上皮癌患者对化疗的近期疗效。

Objective To study the predictive value of MDR1 and CA125 expression in ovarian cancer patients under chemotherapy. Methods The expressions of MDR1 in ovaries specimens of 34 patients with ovarian cancer were detected with fluorescent quantitation reverse transcriptionpolymerase chain reaction. Serum CA125 levels were measured before and after surgical intervention and before each chemotherapy by chemoluminescence method. Results MDR1 expressions were significantly different among 3 groups of ovarian eances, varies benign tumors and normal control cases （P〈0. 01）.Of 34 patients with ovarian cancer, 24 cases had elevated serum CA125 （≥35 U/ml）. The correlation of MDR1 expression and the serum CA125 levels was not remarkable. In 34 patients with ovarian cancer, the half life of CA125 was significantly longer in patients with good outcome from chemotherapy than that in those with poor outcome（〉25 days vs. 〈16 days）（P〈0.05） . Conclusion The detection of MDR1 expression is valuable in predicting the response of ovaries cancer patients to chemotherapy.